134 related articles for article (PubMed ID: 37164802)
21. [Delay in High-Grade Metastatic Prostate Cancer Progression by Dutasteride : A Case Report].
Yamada Y; Fujiwara H; Somiya S; Fujikawa S; Kamiyama Y; Tamaki M; Kanaoka T
Hinyokika Kiyo; 2018 Apr; 64(4):187-192. PubMed ID: 29772622
[TBL] [Abstract][Full Text] [Related]
22. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
23. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer.
Ola IO; Talala K; Tammela T; Taari K; Murtola T; Kujala P; Raitanen J; Auvinen A
Int J Cancer; 2023 Feb; 152(4):672-678. PubMed ID: 36056577
[TBL] [Abstract][Full Text] [Related]
25. [A Case of Prostate Cancer with High Levels of Prostate-Specific Antigen Undetected by Prostate Biopsy].
Shimizu K; Nakano S; Okada Y; Nagahama K; Okubo K; Yasuhara Y
Hinyokika Kiyo; 2019 Mar; 65(3):75-80. PubMed ID: 31067847
[TBL] [Abstract][Full Text] [Related]
26. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
Zhang HF; Wang HL; Xu N; Li SW; Ji GY; Li XM; Pan YZ; Zhang L; Zhao XJ; Gao HW
Chin Med J (Engl); 2004 Jan; 117(1):67-70. PubMed ID: 14733776
[TBL] [Abstract][Full Text] [Related]
27. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.
Bravi CA; Droghetti M; Fossati N; Gandaglia G; Suardi N; Mazzone E; Cucchiara V; Scuderi S; Barletta F; Schiavina R; Osmonov D; Juenemann KP; Boeri L; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768
[TBL] [Abstract][Full Text] [Related]
28. Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate.
Otsubo S; Yokomizo A; Mochida O; Shiota M; Tatsugami K; Inokuchi J; Naito S
World J Urol; 2015 Mar; 33(3):329-33. PubMed ID: 24804843
[TBL] [Abstract][Full Text] [Related]
29. Burned-out Prostate Cancer ? Primary Metastatic Cancer Not Detected on Repeat Biopsy.
Mitsui Y; Sadahira T; Maruyama Y; Wada K; Tanimoto R; Sugimoto M; Araki M; Watanabe M; Yanai H; Watanabe T; Nasu Y
Acta Med Okayama; 2018 Dec; 72(6):605-609. PubMed ID: 30573917
[TBL] [Abstract][Full Text] [Related]
30. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer.
Stock RG; Stone NN; Ianuzzi C; Unger P
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):815-21. PubMed ID: 7591888
[TBL] [Abstract][Full Text] [Related]
31. [A case of prostatic adenocarcinoma clinically presenting as supraclavicular and mediastinal lymphadenopathy].
Tsujino K; Sasada S; Kawahara K; Terada H; Komori C; Suzuki H; Okamoto N; Kobayashi M; Hirashima T; Matsui K; Kawase I
Nihon Kokyuki Gakkai Zasshi; 2007 Aug; 45(8):648-53. PubMed ID: 17763696
[TBL] [Abstract][Full Text] [Related]
32. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
33. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
[TBL] [Abstract][Full Text] [Related]
34. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors in lymph node-positive prostate cancer.
Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
[TBL] [Abstract][Full Text] [Related]
37. Generalized lymphadenopathy: a rare presentation of disseminated prostate cancer.
Oyan B; Engin H; Yalcin S
Med Oncol; 2002; 19(3):177-9. PubMed ID: 12482129
[TBL] [Abstract][Full Text] [Related]
38. Prostate adenocarcinoma manifesting as generalized lymphadenopathy.
Moura FM; Garcia LT; Castro LP; Ferrari TC
Urol Oncol; 2006; 24(3):216-9. PubMed ID: 16678051
[TBL] [Abstract][Full Text] [Related]
39. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
[TBL] [Abstract][Full Text] [Related]
40. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
Shao Q; Song J; Zhou ZJ; Du LD
Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
